No Data
No Data
Individual Investors Are Shanghai Yizhong Pharmaceutical Co., Ltd.'s (SHSE:688091) Biggest Owners and Were Hit After Market Cap Dropped CN¥516m
Shanghai Yizhong (688091.SH) 2023 equity distribution: 0.3 yuan per share increased by 0.3 shares and 0.31 yuan
Shanghai Yizhong (688091.SH) issued an announcement. The company's 2023 equity distribution will be implemented: each share was discovered...
Weak Statutory Earnings May Not Tell The Whole Story For Shanghai Yizhong Pharmaceutical (SHSE:688091)
Shanghai Yizhong Pharmaceutical Co., Ltd.'s (SHSE:688091) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Shanghai Yizhong Pharmaceutical (SHSE:688091) Seems To Use Debt Rather Sparingly
Shanghai Yizhong (688091.SH) Performance Report: Net profit of 2023 was 163 million yuan, up 13.78% year-on-year
Gelonghui, Feb. 26: Shanghai Yizhong (688091.SH) announced the 2023 Annual Results Report. The company achieved operating revenue of 360 million yuan in 2023, an increase of 52.68% over the previous year. Net profit attributable to owners of the parent company was 163 million yuan, up 13.78% from the previous year; net profit attributable to owners of the parent company after deducting non-recurring profit and loss was 162 million yuan, an increase of 57.66% over the previous year.
No Data